Specialist diabetes care company Ascensia has secured the US Food and Drug Administration (FDA) approval and has launched its CONTOUR NEXT LINK 2.4 blood glucose monitoring system (BGMS).
The CONTOUR NEXT LINK 2.4 BGMS relays accurate blood glucose results in a wireless way continuous glucose monitoring (CGM) calibration and insulin dosing, and is designed to be used as a part Medtronic’s MiniMed 630G system with SmartGuard technology.
The device eliminates the chances of manual blood glucose entry errors by automatically delivering blood glucose results to the MiniMed 630G pump.
An incorrect blood glucose entry into the pump can often lead to erroneous bolus calculation on the pump.
Additionally, the meter enables patients to discreetly give a bolus of insulin remotely from the meter to the pump, resulting in ease of use for patients.
Ascensia Diabetes Care US president Robert Schumm said: “Meter accuracy is particularly important for insulin pump users with regard to CGM calibration and insulin bolus calculations.
“The launch of the CONTOUR NEXT LINK 2.4 Meter as part of the MiniMed 630G system means people with diabetes in the US now have access to highly accurate blood glucose monitoring, with the latest advancements in fully integrated insulin pumps.”
The MiniMed 630G system with SmartGuard technology aids in an effective management of treatment of diabetes.
The device sets an alarm to alert users when the CGM sensor detects low blood sugar, and suspends insulin delivery if the alarm is not immediately addressed by the user.
Under a recently renewed alliance with Medtronic, Ascensia will continue to develop and supply CONTOUR NEXT LINK and CONTOUR PLUS LINK BGMSs.